Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018

As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types. He was kind enough to share his thoughts with us in a video interview from the American Brachytherapy Society 2018 Annual Meeting.

When sources are positioned accurately, “No external beam, no proton therapy … none of those other modalities can compete with brachytherapy.”

He particularly appreciates the attributes of high dose rate treatments and the advantageous biological effect of permanent or temporary low dose rate implants that leave little or no trace of their presence for better chances of excellent patient outcomes. 



Dr. Rivard attributes brachytherapy’s technology resurgence in part to the cesium-131 dose uniformity and more favorable half-life (shorter by a factor of six compared to iodine-125). Thanks to treatment planning advances where clinicians can now account for patient composition and new sources that are shielded or dynamically-modulated, an era of highly-targeted radiotherapy delivery is dawning.

If you have been practicing brachytherapy with anything but cesium-131 or are ready to learn how to add brachytherapy to your cancer treatment arsenal, please contact us to arrange a call or meeting.

Don’t miss us and come discover the Power of Blu™ at ASTRO 2019

Don’t miss us and come discover the Power of Blu™ at ASTRO 2019

At Isoray, we recognize the value of industry conferences, specifically when it comes to continuing your education, staying up-to-date with the latest research, and networking with industry colleagues. Our team is looking forward to once again having the opportunity to join the radiation oncologist community at the ASTRO Annual Meeting to discuss the most recent developments in cancer treatment. 

read more